While the masses of spleens and inguinal lymph nodes in MYC mice without tumor were in the normal range and did not change with the TAK-659 treatment, the spleen mass of LMP2A/MYC mice was reduced from 585 mg in the buffer-treated group to 53 mg in the TAK-659-treated group, corresponding to an 11-fold reduction (Fig. 4B and Table S2). The gene discussed is MYC; the disease is neoplasm.